Botulinum TOX TYP a 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTPA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,916
Award facts
- Contract value 100% obligated
- $13,916.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $13,916.23 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Botulinum Toxin Type A 1S. The award, issued on February 3, 2026, with an ultimate completion date of February 19, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain, with a comprehensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's prime vendor contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. This delivery order for Botulinum Toxin Type A represents one of numerous orders DMS Pharmaceutical Group fulfills under this broader PPV-G GEN V framework to support recurring medical supply needs across the global Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FBTPA?
SPE2DR26FBTPA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 3, 2026.
How much is contract SPE2DR26FBTPA worth?
The government has obligated $13,916 on SPE2DR26FBTPA.
Is contract SPE2DR26FBTPA an order under another contract?
Yes. SPE2DR26FBTPA is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTPA competed?
The extent of competition for SPE2DR26FBTPA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award